ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells $14,905.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $59.62, for a total value of $14,905.00. Following the transaction, the vice president now owns 56,988 shares of the company’s stock, valued at approximately $3,397,624.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $64.91, for a total value of $16,227.50.
• On Thursday, June 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $63.80, for a total value of $15,950.00.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $59.23 on Wednesday. The stock has a 50-day moving average of $62.52 and a 200 day moving average of $63.38. ANI Pharmaceuticals, Inc. has a twelve month low of $48.20 and a twelve month high of $70.81. The stock has a market capitalization of $1.24 billion, a price-to-earnings ratio of 36.84 and a beta of 0.75. The company has a current ratio of 3.95, a quick ratio of 3.12 and a debt-to-equity ratio of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 17.15% and a net margin of 6.87%. The business had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the prior year, the firm earned $1.06 earnings per share. The business’s revenue was up 18.5% compared to the same quarter last year. Sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.3 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Rubric Capital Management LP increased its holdings in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after purchasing an additional 277,989 shares during the last quarter. Global Alpha Capital Management Ltd. increased its holdings in shares of ANI Pharmaceuticals by 10.8% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock valued at $32,115,000 after purchasing an additional 56,900 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of ANI Pharmaceuticals by 99.2% in the second quarter. American Century Companies Inc. now owns 99,831 shares of the specialty pharmaceutical company’s stock valued at $6,357,000 after purchasing an additional 49,717 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of ANI Pharmaceuticals by 121.3% in the first quarter. Assenagon Asset Management S.A. now owns 83,944 shares of the specialty pharmaceutical company’s stock valued at $5,803,000 after purchasing an additional 46,008 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of ANI Pharmaceuticals by 6.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after purchasing an additional 33,359 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Truist Financial cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Guggenheim reaffirmed a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $82.75.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.